Symbols / ZNTL $2.56 +1.79%
ZNTL Chart
About
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 165.76M |
| Enterprise Value | -55.28M | Income | -149.32M | Sales | 26.86M |
| Book/sh | 3.50 | Cash/sh | 3.88 | Dividend Yield | — |
| Payout | 0.00% | Employees | 166 | IPO | — |
| P/E | — | Forward P/E | -1.41 | PEG | — |
| P/S | 6.17 | P/B | 0.73 | P/C | — |
| EV/EBITDA | 0.36 | EV/Sales | -2.06 | Quick Ratio | 7.55 |
| Current Ratio | 7.76 | Debt/Eq | 16.00 | LT Debt/Eq | — |
| EPS (ttm) | -2.08 | EPS next Y | -1.82 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 | ROA | -24.51% |
| ROE | -49.18% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -5.68% | Profit Margin | 0.00% | Shs Outstand | 64.75M |
| Shs Float | 47.41M | Short Float | 7.49% | Short Ratio | 5.96 |
| Short Interest | — | 52W High | 3.95 | 52W Low | 1.01 |
| Beta | 1.71 | Avg Volume | 1.32M | Volume | 319.06K |
| Target Price | $5.31 | Recom | Buy | Prev Close | $2.52 |
| Price | $2.56 | Change | 1.79% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.31
Mean price target
2. Current target
$2.56
Latest analyst target
3. DCF / Fair value
$-17.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.56
Low
$2.00
High
$10.00
Mean
$5.31
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $4 |
| 2025-08-07 | main | Wells Fargo | Equal-Weight → Equal-Weight | $5 |
| 2025-05-15 | reit | Wedbush | Neutral → Neutral | $4 |
| 2025-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-28 | reit | Wedbush | Neutral → Neutral | $4 |
| 2025-03-27 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-01-30 | main | Wells Fargo | Equal-Weight → Equal-Weight | $6 |
| 2025-01-29 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-01-28 | main | UBS | Neutral → Neutral | $2 |
| 2024-11-15 | main | Guggenheim | Buy → Buy | $8 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-09-16 | reit | Oppenheimer | Outperform → Outperform | $20 |
| 2024-08-12 | up | Wedbush | Underperform → Neutral | $4 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-06-20 | down | UBS | Buy → Neutral | $5 |
| 2024-06-18 | down | Wells Fargo | Overweight → Equal-Weight | $9 |
| 2024-06-18 | main | Stifel | Buy → Buy | $10 |
| 2024-06-18 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-06-18 | main | Oppenheimer | Outperform → Outperform | $25 |
- Triple-Negative breast and Cyclin E1 ovarian cancer data headed to AACR 2026 - Stock Titan ue, 17 Mar 2026 20
- Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday - MarketBeat Wed, 18 Mar 2026 06
- A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying - Yahoo Finance Sun, 11 Jan 2026 08
- $ZNTL stock is down 13% today. Here's what we see in our data. - Quiver Quantitative hu, 05 Mar 2026 19
- Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m - Investing.com hu, 08 Jan 2026 08
- Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval (ZNTL) - Seeking Alpha ue, 18 Nov 2025 08
- Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st Wed, 07 Jan 2026 08
- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Brokerages - MarketBeat hu, 19 Mar 2026 06
- Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners - Yahoo Finance hu, 08 Jan 2026 08
- Cancer drug developer Zentalis to speak at three major investor events - Stock Titan Wed, 18 Feb 2026 08
- Does Zentalis (ZNTL) Pairing DENALI Progress With Insider Buying Reveal a Shifting Oncology Strategy? - simplywall.st Sun, 11 Jan 2026 08
- Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC - MarketBeat Sun, 15 Mar 2026 07
- $ZNTL stock is up 28% today. Here's what we see in our data. - Quiver Quantitative ue, 06 Jan 2026 08
- Squadron reports 3,676,900-share stake in Zentalis (ZNTL) - Stock Titan ue, 03 Mar 2026 21
- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the company - Yahoo Finance Wed, 23 Jul 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 40224 | 97557 | — | Sale at price 2.39 - 2.43 per share. | VULTAGGIO VINCENT | Officer | — | 2026-02-10 00:00:00 | D |
| 1 | 8755 | 21239 | — | Sale at price 2.39 - 2.43 per share. | EASTLAND JULIA MARIE | Chief Executive Officer | — | 2026-02-09 00:00:00 | D |
| 2 | 3297 | 7998 | — | Sale at price 2.39 - 2.43 per share. | BRUNS INGMAR | Officer | — | 2026-02-09 00:00:00 | D |
| 3 | 3096 | 7875 | — | Sale at price 2.52 - 2.55 per share. | VULTAGGIO VINCENT | Officer | — | 2026-02-03 00:00:00 | D |
| 4 | 7500000 | 9975000 | — | Sale at price 1.33 per share. | MATRIX CAPITAL MANAGEMENT COMPANY, LP | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-15 00:00:00 | I |
| 5 | 57603 | — | — | Stock Award(Grant) at price 0.00 per share. | MYERS SCOTT DUNSETH | Director | — | 2025-06-17 00:00:00 | D |
| 6 | 57603 | — | — | Stock Award(Grant) at price 0.00 per share. | WALKER LUKE NATHANIEL | Director | — | 2025-06-17 00:00:00 | D |
| 7 | 57603 | — | — | Stock Award(Grant) at price 0.00 per share. | JOHNSON DAVID MICHAEL | Director | — | 2025-06-17 00:00:00 | D |
| 8 | 57603 | — | — | Stock Award(Grant) at price 0.00 per share. | SKVARKA JAN | Director | — | 2025-06-17 00:00:00 | D |
| 9 | 57603 | — | — | Stock Award(Grant) at price 0.00 per share. | KARIUKI ENOCH | Director | — | 2025-06-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 4.57M | -45.90K | 11.97K | 103.97K |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -207.94M | -229.60M | -231.85M | -267.98M |
| TotalUnusualItems | 21.77M | -22.95M | 5.99M | 51.98M |
| TotalUnusualItemsExcludingGoodwill | 21.77M | -22.95M | 5.99M | 51.98M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -165.84M | -292.19M | -236.81M | -158.72M |
| ReconciledDepreciation | 1.29M | 1.39M | 1.43M | 544.00K |
| EBITDA | -186.17M | -252.55M | -225.86M | -216.00M |
| EBIT | -187.46M | -253.94M | -227.29M | -216.54M |
| NormalizedIncome | -183.04M | -269.29M | -242.78M | -210.60M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -165.84M | -292.19M | -236.81M | -158.72M |
| TotalExpenses | 254.88M | 253.94M | 227.29M | 216.54M |
| TotalOperatingIncomeAsReported | -191.19M | -299.51M | -227.29M | -216.54M |
| DilutedAverageShares | 71.08M | 65.41M | 52.86M | 42.69M |
| BasicAverageShares | 71.08M | 65.41M | 52.86M | 42.69M |
| DilutedEPS | -2.33 | -4.47 | -4.48 | -3.72 |
| BasicEPS | -2.33 | -4.47 | -4.48 | -3.72 |
| DilutedNIAvailtoComStockholders | -165.84M | -292.19M | -236.81M | -158.72M |
| NetIncomeCommonStockholders | -165.84M | -292.19M | -236.81M | -158.72M |
| NetIncome | -165.84M | -292.19M | -236.81M | -158.72M |
| MinorityInterests | 28.00K | 114.00K | 307.00K | 7.37M |
| NetIncomeIncludingNoncontrollingInterests | -165.87M | -292.31M | -237.11M | -166.09M |
| NetIncomeContinuousOperations | -165.87M | -292.31M | -237.11M | -166.09M |
| EarningsFromEquityInterestNetOfTax | 0.00 | -16.01M | -16.28M | -1.83M |
| TaxProvision | 177.00K | -601.00K | -469.00K | -297.00K |
| PretaxIncome | -165.69M | -276.89M | -221.30M | -164.56M |
| OtherIncomeExpense | 21.77M | -22.95M | 5.99M | 51.98M |
| SpecialIncomeCharges | -3.74M | -45.57M | 0.00 | 51.58M |
| GainOnSaleOfBusiness | 0.00 | 0.00 | 51.58M | |
| OtherSpecialCharges | 45.57M | |||
| ImpairmentOfCapitalAssets | 3.74M | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | 25.50M | 22.62M | 5.99M | 401.00K |
| OperatingIncome | -187.46M | -253.94M | -227.29M | -216.54M |
| OperatingExpense | 254.88M | 253.94M | 227.29M | 216.54M |
| ResearchAndDevelopment | 167.77M | 189.59M | 172.73M | 175.60M |
| SellingGeneralAndAdministration | 87.11M | 64.35M | 54.55M | 40.94M |
| GeneralAndAdministrativeExpense | 87.11M | 64.35M | 54.55M | 40.94M |
| OtherGandA | 87.11M | 64.35M | 54.55M | 40.94M |
| TotalRevenue | 67.42M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 67.42M | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 71.28M | 70.77M | 59.28M | 45.49M |
| ShareIssued | 71.28M | 70.77M | 59.28M | 45.49M |
| TotalDebt | 39.58M | 43.15M | 45.17M | 44.46M |
| TangibleBookValue | 337.19M | 433.55M | 430.07M | 360.22M |
| InvestedCapital | 337.19M | 437.28M | 433.80M | 363.95M |
| WorkingCapital | 333.34M | 427.35M | 395.29M | 306.83M |
| NetTangibleAssets | 337.19M | 433.55M | 430.07M | 360.22M |
| CapitalLeaseObligations | 39.58M | 43.15M | 45.17M | 44.46M |
| CommonStockEquity | 337.19M | 437.28M | 433.80M | 363.95M |
| TotalCapitalization | 337.19M | 437.28M | 433.80M | 363.95M |
| TotalEquityGrossMinorityInterest | 337.19M | 437.39M | 434.02M | 364.48M |
| MinorityInterest | 0.00 | 107.00K | 221.00K | 528.00K |
| StockholdersEquity | 337.19M | 437.28M | 433.80M | 363.95M |
| GainsLossesNotAffectingRetainedEarnings | 558.00K | 2.19M | -1.35M | -125.00K |
| OtherEquityAdjustments | 558.00K | 2.19M | -1.35M | -125.00K |
| RetainedEarnings | -1.05B | -888.56M | -596.37M | -359.56M |
| AdditionalPaidInCapital | 1.39B | 1.32B | 1.03B | 723.59M |
| CapitalStock | 71.00K | 70.00K | 59.00K | 45.00K |
| CommonStock | 71.00K | 70.00K | 59.00K | 45.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 93.15M | 114.30M | 105.29M | 90.03M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 40.43M | 44.93M | 48.64M | 46.08M |
| OtherNonCurrentLiabilities | 849.00K | 1.78M | 2.62M | |
| NonCurrentDeferredLiabilities | 0.00 | 853.00K | 1.62M | |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 853.00K | 1.62M | |
| LongTermDebtAndCapitalLeaseObligation | 39.58M | 43.15M | 45.17M | 44.46M |
| LongTermCapitalLeaseObligation | 39.58M | 43.15M | 45.17M | 44.46M |
| CurrentLiabilities | 52.73M | 69.37M | 56.65M | 43.94M |
| CurrentDebtAndCapitalLeaseObligation | 1.45M | |||
| CurrentCapitalLeaseObligation | 1.45M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 9.25M | |||
| PayablesAndAccruedExpenses | 52.73M | 69.37M | 56.65M | 43.94M |
| CurrentAccruedExpenses | 45.29M | 54.44M | 45.40M | 32.35M |
| Payables | 7.44M | 14.93M | 11.25M | 11.59M |
| TotalTaxPayable | 971.00K | |||
| IncomeTaxPayable | 971.00K | |||
| AccountsPayable | 7.44M | 14.93M | 11.25M | 11.59M |
| TotalAssets | 430.34M | 551.69M | 539.31M | 454.51M |
| TotalNonCurrentAssets | 44.27M | 54.97M | 87.38M | 103.74M |
| OtherNonCurrentAssets | 7.04M | 9.50M | 12.35M | 9.67M |
| NonCurrentPrepaidAssets | 9.72M | 7.04M | ||
| InvestmentsAndAdvances | 0.00 | 21.21M | 37.49M | |
| LongTermEquityInvestment | 0.00 | 21.21M | 37.49M | |
| InvestmentsinJointVenturesatCost | 21.21M | 37.49M | ||
| InvestmentsinAssociatesatCost | 0.00 | 21.21M | 37.49M | |
| GoodwillAndOtherIntangibleAssets | 0.00 | 3.74M | 3.74M | 3.74M |
| Goodwill | 0.00 | 3.74M | 3.74M | 3.74M |
| NetPPE | 37.23M | 41.73M | 50.08M | 52.84M |
| AccumulatedDepreciation | -4.27M | -3.15M | -2.06M | -792.00K |
| GrossPPE | 41.50M | 44.88M | 52.14M | 53.63M |
| Leases | 4.17M | 4.24M | 4.89M | 4.51M |
| ConstructionInProgress | 0.00 | 173.00K | 37.00K | 34.00K |
| OtherProperties | 35.91M | 38.98M | 44.99M | 46.75M |
| MachineryFurnitureEquipment | 1.42M | 1.49M | 2.21M | 2.33M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 386.07M | 496.72M | 451.93M | 350.77M |
| OtherCurrentAssets | 9.98M | 13.80M | 14.56M | 10.64M |
| RestrictedCash | 0.00 | 243.00K | ||
| PrepaidAssets | 14.56M | 10.64M | ||
| Receivables | 5.00M | 0.00 | 7.04M | 4.44M |
| OtherReceivables | 5.00M | 6.53M | 4.18M | |
| AccruedInterestReceivable | 508.00K | 258.00K | ||
| AccountsReceivable | 4.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 371.08M | 482.92M | 437.37M | 339.89M |
| OtherShortTermInvestments | 337.18M | 454.88M | 394.30M | 280.17M |
| CashAndCashEquivalents | 33.90M | 28.04M | 43.07M | 59.71M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -171.08M | -208.41M | -166.30M | -160.20M |
| IssuanceOfCapitalStock | 349.00K | 237.30M | 261.04M | 179.67M |
| CapitalExpenditure | -221.00K | -583.00K | -2.55M | -6.11M |
| IncomeTaxPaidSupplementalData | 359.00K | 140.00K | 12.00K | 20.00K |
| EndCashPosition | 36.53M | 30.72M | 45.70M | 62.58M |
| BeginningCashPosition | 30.72M | 45.70M | 62.58M | 56.27M |
| ChangesInCash | 5.81M | -14.98M | -16.89M | 6.31M |
| FinancingCashFlow | 108.00K | 237.30M | 261.04M | 178.52M |
| CashFlowFromContinuingFinancingActivities | 108.00K | 237.30M | 261.04M | 178.52M |
| NetOtherFinancingCharges | -241.00K | -1.15M | ||
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 349.00K | 237.30M | 261.04M | 179.67M |
| CommonStockIssuance | 349.00K | 237.30M | 261.04M | 179.67M |
| InvestingCashFlow | 176.56M | -44.46M | -114.18M | -18.11M |
| CashFlowFromContinuingInvestingActivities | 176.56M | -44.46M | -114.18M | -18.11M |
| NetInvestmentPurchaseAndSale | 176.72M | -43.88M | -111.63M | 2.31M |
| SaleOfInvestment | 304.68M | 505.31M | 421.53M | 365.82M |
| PurchaseOfInvestment | -127.96M | -549.18M | -533.16M | -363.51M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -14.32M | |
| PurchaseOfBusiness | 0.00 | 0.00 | -14.32M | |
| NetPPEPurchaseAndSale | -156.00K | -583.00K | -2.55M | -6.11M |
| SaleOfPPE | 65.00K | 0.00 | 0.00 | |
| PurchaseOfPPE | -221.00K | -583.00K | -2.55M | -6.11M |
| OperatingCashFlow | -170.86M | -207.82M | -163.75M | -154.09M |
| CashFlowFromContinuingOperatingActivities | -170.86M | -207.82M | -163.75M | -154.09M |
| ChangeInWorkingCapital | -16.54M | 5.86M | 13.25M | 16.61M |
| ChangeInOtherWorkingCapital | 264.00K | 623.00K | 4.33M | 1.35M |
| ChangeInPayablesAndAccruedExpense | -18.02M | 10.92M | 15.53M | 13.96M |
| ChangeInPayable | -18.02M | 10.92M | 15.53M | 13.96M |
| ChangeInAccountPayable | -18.02M | 10.92M | 15.53M | 13.96M |
| ChangeInPrepaidAssets | 6.22M | -5.68M | -6.61M | 1.29M |
| ChangeInReceivables | -5.00M | 0.00 | 0.00 | 413.00K |
| ChangesInAccountReceivables | -5.00M | 0.00 | 0.00 | 413.00K |
| OtherNonCashItems | -47.42M | 15.04M | ||
| StockBasedCompensation | 67.27M | 54.82M | 46.84M | 35.74M |
| UnrealizedGainLossOnInvestmentSecurities | -5.23M | 0.00 | 0.00 | |
| AssetImpairmentCharge | 3.74M | 4.95M | 0.00 | 8.80M |
| AmortizationOfSecurities | -8.00M | -13.16M | -3.73M | 908.00K |
| DeferredTax | 0.00 | -853.00K | -769.00K | -2.51M |
| DeferredIncomeTax | 0.00 | -853.00K | -769.00K | -2.51M |
| DepreciationAmortizationDepletion | 1.29M | 1.39M | 1.43M | 544.00K |
| DepreciationAndAmortization | 1.29M | 1.39M | 1.43M | 544.00K |
| OperatingGainsLosses | -92.00K | 16.42M | 16.34M | -48.08M |
| EarningsLossesFromEquityInvestments | 0.00 | 16.01M | 16.28M | 1.83M |
| GainLossOnSaleOfPPE | -13.00K | 406.00K | 56.00K | 15.00K |
| GainLossOnSaleOfBusiness | -79.00K | 0.00 | 0.00 | -49.93M |
| NetIncomeFromContinuingOperations | -165.87M | -292.31M | -237.11M | -166.09M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ZNTL
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|